Sector Alpha Week of 2026-09-17
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-17

Raymond James Financial, Inc.

RJF
Financials · Asset Management

Raymond James Financial, Inc.'s earnings have outrun its stock. EPS grew +6.2% in a year against a −5.5% price move.

Biggest watch item: the P/BV sits at the 68th percentile of its own range — the multiple has already done part of the work.

The price is topping out (6 weeks in) while the P/BV sits at the 68th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +34.1% year on year, with the the net margin at 15.0%. What settles it: the next one or two quarters of delivery.

Stage
Consistent
fundamental trajectory, 12 quarters
Price
$165
−5.5% 1Y
P/BV
2.5×
68th pctile
of its own 5-year range
Revenue (Jun 26)
$3.9 B
+15.6% YoY
Profit (Jun 26)
$0.6 B
+34.1% YoY
Net margin
15.0%
+2.1 pp YoY
ROE
18%
FY25
ROA
2.58%
latest
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Raymond James Financial, Inc. trades at $165, losing momentum at the top and 6 weeks into that stage. That is +2.2% against its own 200-day average. It sits at 59% of a 52-week range of $141 to $181. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 12 straight weeks.

Today the stock is losing momentum at the top — week 6 of stage 3. At $165 it trades +2.2% versus its 200-day average and sits at 59% of its 52-week range ($141–$181).

Sep 26: $165 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+2.2% versus the 200-day line, week 6 of stage 3
Price50-day avg200-day avg
S3S2S2S2S2S1$188$163$138$113$87.6$$165$161Sep 23Jun 24Mar 25Dec 25Sep 26
S3S2S2S2S2S1$188$163$138$113$87.6$$165$161Sep 23Mar 25Sep 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (533 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Sep 26

Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +393% while the S&P 500 moved +255% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 12 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each $1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.

Raymond James Financial, Inc. trades at 2.5× P/BV, mid-range by its own standards (68th percentile). Its long-run median P/BV is 2.5×, measured across 5.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/BV of 2.5× is mid-range by its own standards (68th percentile), against a long-run median of 2.5× measured over 5.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/BV 2.5× vs a 2.5× long-run median P/BV, weekly (left axis); book value per share, quarterly steps drawn weekly (right axis). 5.2-year window; brief peaks above 2.9× shown pinned at the top. The book value / share bars are red where the reading is lower than the quarter before.
mid-range by its own standards (68th percentile)
P/BVMedianBook value / share (quarterly)
3.0×$69.62.7×$52.22.4×$34.82.1×$17.41.8×$0.0×$2.56×$64Jul 21Oct 22Feb 24May 25Sep 26
3.0×$69.62.7×$52.22.4×$34.82.1×$17.41.8×$0.0×$2.56×$64Jul 21Feb 24Sep 26
PEG 0.88 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 20 quarters.
below 1.0, the growth looks cheap against the multiple
PEGPEG = 1.0
1.9×1.6×1.3×1.0×0.7××0.88×Sep 21Sep 22Dec 23Mar 25Jun 26
1.9×1.6×1.3×1.0×0.7××0.88×Sep 21Dec 23Jun 26
P/BV
2.5×
68th percentile of 5y
PEG
0.66
as reported

Why the multiple sits where it does: over the past year book value grew while the price moved −5.5% — the price ran ahead of the book, pushing the multiple up its own range.

The price move, decomposed: over 5y, of the +13.0%/yr price move, ~+11.6%/yr came from book-value growth and ~+1.4 pp from the multiple (expanding). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the book-value line underneath it, not the multiple.

03 · Stage: Consistent

Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Raymond James Financial, Inc. reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROE at 17.9% and holding. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +9.7% in FY25, profit +2.9% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
13%23%11%18%9.1%12%7.1%6.8%5.0%1.4%%%9.7%2.9%FY21FY23FY25
13%23%11%18%9.1%12%7.1%6.8%5.0%1.4%%%9.7%2.9%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising, profit stabilising
RevenueProfitEPS
13%31%11%22%9.2%12%7.1%3.0%5.0%−6.3%%%10.5%7.5%12.5%Sep 23Dec 24Jun 26
13%31%11%22%9.2%12%7.1%3.0%5.0%−6.3%%%10.5%7.5%12.5%Sep 23Dec 24Jun 26
ROE Trailing-twelve-month net profit as a share of quarter-end equity, %.
the return curve, computed quarterly
ROE
18.4%17.7%17.1%16.5%15.8%%17.9%Sep 23Mar 24Dec 24Sep 25Jun 26
18.4%17.7%17.1%16.5%15.8%%17.9%Sep 23Dec 24Jun 26
Revenue growth
Steady high
latest +10.5% · span +5.6% to +12.8%
Profit growth
Recovering
latest +7.5% · span −3.7% to +25.4%
EPS growth
Steady high
latest +12.5% · span −0.3% to +28.4%
ROE
Steady high
latest 17.9% · span 16.0%–18.2%

Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+9.7%+8.5%
Profit+2.9%+12.2%
EPS+6.2%+13.8%
Stock price−5.5%+15.2%+13.0%+15.9%
Revenue YoY (Jun 26)
+15.6%
latest quarter vs a year ago
Profit YoY (Jun 26)
+34.1%
latest quarter vs a year ago
Revenue 10y
9.6%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

41.6/100 — rank 19 of 29 in Asset Management · 80% evidence confidence

Raymond James Financial, Inc. scores 41.6 out of 100 against the 29 companies it is compared with in Asset Management, ranking 19. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 15.6 + 10.9 + 6.7 + 8.4 = 41.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.

05 · Revenue

Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fees from its businesses.

Raymond James Financial, Inc. reported $3.9 B of income in the Jun 26 quarter, +15.6% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 9.6% a year. The last full year, FY25, came in at $14.1 B. The last four reported quarters add to $15.3 B.

FY25 revenue came in at $14.1 B (+9.7% on the year), capping 4 years at 9.6% compound. The latest quarter (Jun 26) printed $3.9 B, +15.6% year on year — the 12th consecutive quarter of year-over-year growth.

FY25 revenue $14.1 B (+9.7% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
9.6% a year over 4 years
RevenueYoY growth
1513%1111%7.69.1%3.87.1%0.05.0%$ B%$14B9.7%FY21FY23FY25
1513%1111%7.69.1%3.87.1%0.05.0%$ B%$14B9.7%FY21FY23FY25
Jun 26: $3.9 B (+15.6% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
12th straight quarter of growth
Revenue (quarterly)YoY growth
4.219%3.215%2.111%1.17.9%0.04.3%$ B%$4B15.6%Sep 23Dec 24Jun 26
4.219%3.215%2.111%1.17.9%0.04.3%$ B%$4B15.6%Sep 23Dec 24Jun 26

Pace check: the last four quarters averaged +10.6% growth against the decade's 9.6% — the current year is running in line with its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +10.5% over the last 4 quarters against +10.9%/yr over the last 8 — stabilising; TTM profit +7.5% vs +9.8%/yr — stabilising.

06 · Net margin

Net margin Net margin — what the bank keeps of every $100 of revenue after every cost, provision and tax. With big fee businesses in the mix, it is the cleanest margin we can read for this bank.

Raymond James Financial, Inc.'s net margin is 15.0% in the Jun 26 quarter, +2.1 percentage points against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 13.7% to 16.1%. The current quarter sits inside that band.

The latest quarter's net margin is 15.0%, +2.1 pp against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 13.7%–16.1%.

Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.

FY25: 15.1% Net margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a 13.7–16.1% band over 5 years
net marginYoY change (pp)
16.3%1.5%15.6%0.8%14.9%0.1%14.2%−0.5%13.5%−1.2%%%15.1%−1%FY21FY23FY25
16.3%1.5%15.6%0.8%14.9%0.1%14.2%−0.5%13.5%−1.2%%%15.1%−1%FY21FY23FY25
Jun 26: 15.0% net margin (+2.1 pp YoY) Quarterly net margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Net profit as a share of total revenue, per quarter.
Net marginYoY change (pp)
18%3.6%16%2.0%15%0.5%14%−1.1%13%−2.7%%%15%2.1%Sep 23Dec 24Jun 26
18%3.6%16%2.0%15%0.5%14%−1.1%13%−2.7%%%15%2.1%Sep 23Dec 24Jun 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Raymond James Financial, Inc. earned $0.6 B of net profit in the Jun 26 quarter, +34.1% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was $2.1 B. The 4-year compound rate is 11.1%. That is 15.0% of the quarter's revenue. The same quarter a year earlier earned $0.4 B.

Jun 26 profit was $0.6 B, +34.1% year on year — the 2nd consecutive quarter of growth. On the full year, FY25 printed $2.1 B (+2.9%), and the 4-year compound rate is 11.1%.

FY25 profit $2.1 B (+2.9% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
11.1% a year over 4 years
Net profitYoY growth
2.320%1.716%1.211%0.66.3%0.01.6%$ B%$2B2.9%FY21FY23FY25
2.320%1.716%1.211%0.66.3%0.01.6%$ B%$2B2.9%FY21FY23FY25
Jun 26: $0.6 B (+34.1% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
2nd straight quarter of growth
Net profit (quarterly)YoY growth
0.643%0.529%0.315%0.20.0%0.0−14%$ B%$1B34.1%Sep 23Dec 24Jun 26
0.643%0.529%0.315%0.20.0%0.0−14%$ B%$1B34.1%Sep 23Dec 24Jun 26

Why profit moved: revenue contributed +15.6% and the margin +2.1 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +9.4% vs revenue +10.6%. Profit and revenue are moving roughly in step.

08 · Asset quality — the ladder

Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.

Loan-book quality history is not available for Raymond James Financial, Inc., so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.

We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.

Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.

09 · The loan book

The loan book We read the loan book through revenue — when the book and the businesses grow, revenue grows with them. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.

Raymond James Financial, Inc.'s revenue grew +9.7% in FY25 to $14.1 B, so the book is growing. The latest quarter ran +15.6% year on year. The net margin on that income is 15.0%, +2.1 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.

FY25 revenue was $14.1 B, +9.7% on the year, and the latest quarter ran +15.6% year on year. The net margin on that revenue is 15.0% this quarter (+2.1 pp YoY) — growth with a widening margin on it.

FY25: revenue $14.1 B (+9.7% YoY) with the net margin at 15.1% Revenue by fiscal year, $ B (bars, left); net margin, % (line, right). 5-year window. A bar is red when it is lower than the year before.
RevenueNet margin
1516.3%1115.6%7.614.9%3.814.2%0.013.5%$ B%$14B15.1%FY21FY22FY23FY24FY25
1516.3%1115.6%7.614.9%3.814.2%0.013.5%$ B%$14B15.1%FY21FY23FY25

The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — with quarterly loan-quality numbers missing here, revenue growth and margin are the two we watch.

10 · Returns on equity and assets

Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.

Raymond James Financial, Inc. earns a return on equity of 17% in FY25. Its trough over the ladder below was 16% in FY22. On the asset side every $100 of the balance sheet earned about $2.58, which is the return before leverage is applied.

FY25 ROE came in at 17%. On assets, the latest reading is about 2.58% — every $100 the bank deploys earns roughly $2.58 a year. That clears the bar a bank must beat for its book value to compound.

FY25: ROE 17%, ROA 2.50% Return on equity by fiscal year, % (line, left); return on assets, % (line, right). 5-year window. A lender is judged on ROE and ROA — return on invested capital does not apply to a bank.
the full ladder
ROEROA
17.8%2.7%17.3%2.6%16.9%2.4%16.4%2.2%15.9%2.1%%%16.9%2.5%FY21FY23FY25
17.8%2.7%17.3%2.6%16.9%2.4%16.4%2.2%15.9%2.1%%%16.9%2.5%FY21FY23FY25
Jun 26: ROE 18.8% (TTM), ROA 2.70% Trailing-twelve-month return on equity (left) and on assets (right), per quarter, %. Last 12 quarters, anchored to the annual figure.
ROE (TTM)ROA (TTM)
20.2%2.7%19.5%2.6%18.8%2.5%18.0%2.4%17.3%2.3%%%18.8%2.7%Sep 23Dec 24Jun 26
20.2%2.7%19.5%2.6%18.8%2.5%18.0%2.4%17.3%2.3%%%18.8%2.7%Sep 23Dec 24Jun 26

Why: the ROE ladder shows the move; the deposit-cost and provisioning drivers behind it sit below what we hold.

11 · Dividend

Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.

Raymond James Financial, Inc. paid $2.12 per share over the last four reported quarters. The most recent declaration was $0.54 for Jun 26. Against the current price of $165 that is a trailing yield of 1.29%, measured on dividends already paid rather than on a forecast.

Raymond James Financial, Inc. paid $2.12 per share across the last four reported quarters, most recently $0.54 for Jun 26. Against the current price of $165 the trailing twelve months work out to 1.29% — trailing dividends measured against today's price, not a forward estimate.

Dividend per share by quarter Declared dividend per share, $ B, per reported quarter. 12 quarters on file.
latest $0.54 (Jun 26)
Dividend per share
0.60.40.30.10.0$ B$1BSep 23Mar 24Dec 24Sep 25Jun 26
0.60.40.30.10.0$ B$1BSep 23Dec 24Jun 26
12 · Debt

Debt

For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.

A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.

13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

4.6% of Raymond James Financial, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 7.8 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 4.6% of the float is sold short, and at typical trading volumes it would take about 7.8 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
4.6%
of the tradable float
Days to cover
7.8
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Raymond James Financial, Inc.: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.

The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.

15 · Related companies · Asset Management
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Victory Capital Holdings, Inc.VCTR 67.4/100Favorable setup76% evidence LEADER 25.0/35 Income 64.1% · PAT 29.1% 71% evidence 16.1/25 ROA 3.6% · ROE 6.4% · GNPA — 68% evidence 7.6/20 P/BV 2.29× · P/BV÷ROE 0.36 70% evidence 18.7/20 RS sector 22.7% · RS bench 24.4% · 1Y 54.7%12 of 12 weeks ahead 100% evidence
Exact sum: 25 + 16.1 + 7.6 + 18.7 = 67.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Principal Financial Group, Inc.PFG 62.3/100Mixed-positive evidence80% evidence LEADER 22.5/35 Income 3.7% · PAT 36.9% 81% evidence 11.2/25 ROA 0.4% · ROE 13.3% · GNPA — 68% evidence 14.1/20 P/BV 1.81× · P/BV÷ROE 0.14 70% evidence 14.5/20 RS sector 11.4% · RS bench 13.1% · 1Y 42.7%10 of 12 weeks ahead 100% evidence
Exact sum: 22.5 + 11.2 + 14.1 + 14.5 = 62.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3SEI Investments CompanySEIC 59.2/100Mixed-positive evidence60% evidence LEADER 18.0/35 Income — · PAT — 26% evidence 17.0/25 ROA 5.2% · ROE 7.7% · GNPA — 68% evidence 6.0/20 P/BV 4.21× · P/BV÷ROE 0.55 70% evidence 18.2/20 RS sector 9.7% · RS bench 11.2% · 1Y 20.6%12 of 12 weeks ahead 100% evidence
Exact sum: 18 + 17 + 6 + 18.2 = 59.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
4Ameriprise Financial, Inc.AMP 57.0/100Mixed-positive evidence64% evidence BREAKING OUT 18.3/35 Income 10.6% · PAT 22.4% 62% evidence 16.4/25 ROA — · ROE 17.9% · GNPA — 34% evidence 7.3/20 P/BV 6.37× · P/BV÷ROE 0.36 70% evidence 15.0/20 RS sector 2.6% · RS bench 3.9% · 1Y 10.5%10 of 12 weeks ahead 100% evidence
Exact sum: 18.3 + 16.4 + 7.3 + 15 = 57 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5T. Rowe Price Group, Inc.TROW 55.6/100Mixed-positive evidence80% evidence ASLEEP 16.0/35 Income 7% · PAT 9.1% 81% evidence 20.1/25 ROA 12% · ROE 16.2% · GNPA — 68% evidence 14.7/20 P/BV 2× · P/BV÷ROE 0.12 70% evidence 4.8/20 RS sector -8.6% · RS bench -7.3% · 1Y -3.4%5 of 12 weeks ahead 100% evidence
Exact sum: 16 + 20.1 + 14.7 + 4.8 = 55.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Brookfield Asset Management Ltd.BAM 54.8/100Mixed-positive evidence80% evidence ASLEEP 28.5/35 Income 31.9% · PAT 32.8% 81% evidence 17.9/25 ROA 5.6% · ROE 10.2% · GNPA — 68% evidence 4.4/20 P/BV 9.53× · P/BV÷ROE 0.94 70% evidence 4.0/20 RS sector -16.5% · RS bench -15.4% · 1Y -24.7%4 of 12 weeks ahead 100% evidence
Exact sum: 28.5 + 17.9 + 4.4 + 4 = 54.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -16.5% and the one-year return is -24.7%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
7Northern Trust CorporationNTRS 54.8/100Mixed-positive evidence64% evidence FADING 22.9/35 Income 15.7% · PAT 29.4% 62% evidence 12.7/25 ROA — · ROE 6% · GNPA — 34% evidence 7.1/20 P/BV 2.37× · P/BV÷ROE 0.4 70% evidence 12.1/20 RS sector 6% · RS bench 7.6% · 1Y 34.3%11 of 12 weeks ahead 100% evidence
Exact sum: 22.9 + 12.7 + 7.1 + 12.1 = 54.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8BlackRock, Inc.BLK 53.6/100Mixed-positive evidence80% evidence ASLEEP 17.2/35 Income 26.5% · PAT 2.7% 81% evidence 18.3/25 ROA 3.4% · ROE 14.9% · GNPA — 68% evidence 12.8/20 P/BV 2.31× · P/BV÷ROE 0.15 70% evidence 5.3/20 RS sector -10.4% · RS bench -9.2% · 1Y -9.2%3 of 12 weeks ahead 100% evidence
Exact sum: 17.2 + 18.3 + 12.8 + 5.3 = 53.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Affiliated Managers Group, Inc.AMG 52.3/100Mixed-positive evidence60% evidence FADING 20.2/35 Income — · PAT — 26% evidence 14.8/25 ROA 1.6% · ROE 6.1% · GNPA — 68% evidence 6.4/20 P/BV 2.94× · P/BV÷ROE 0.48 70% evidence 10.9/20 RS sector 4.4% · RS bench 5.9% · 1Y 41.2%10 of 12 weeks ahead 100% evidence
Exact sum: 20.2 + 14.8 + 6.4 + 10.9 = 52.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10StepStone Group Inc.STEP 52.3/100Thin evidence · provisional55% evidence TURNING 23.3/35 Income 69.7% · PAT — 45% evidence 13.1/25 ROA 6.9% · ROE 0.5% · GNPA — 68% evidence 9.8/20 P/BV -9.31× · P/BV÷ROE — 10% evidence 6.1/20 RS sector -18.5% · RS bench -17.7% · 1Y -25.5%3 of 12 weeks ahead 100% evidence
Exact sum: 23.3 + 13.1 + 9.8 + 6.1 = 52.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11Corebridge Financial, Inc.CRBG 52.2/100Thin evidence · provisional55% evidence BREAKING OUT 19.1/35 Income 14.6% · PAT -71.3% 45% evidence 4.8/25 ROA 0% · ROE -0.5% · GNPA — 68% evidence 9.8/20 P/BV 1.01× · P/BV÷ROE — 10% evidence 18.5/20 RS sector 9.4% · RS bench 10.7% · 1Y 7%12 of 12 weeks ahead 100% evidence
Exact sum: 19.1 + 4.8 + 9.8 + 18.5 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12Blackstone Inc.BX 51.3/100Mixed-positive evidence80% evidence ASLEEP 23.4/35 Income 17.2% · PAT 19.1% 81% evidence 17.2/25 ROA 5% · ROE 10.8% · GNPA — 68% evidence 4.5/20 P/BV 9.82× · P/BV÷ROE 0.91 70% evidence 6.2/20 RS sector -15.2% · RS bench -14.3% · 1Y -34.2%5 of 12 weeks ahead 100% evidence
Exact sum: 23.4 + 17.2 + 4.5 + 6.2 = 51.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -15.2% and the one-year return is -34.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
13Janus Henderson Group plcJHG 51.0/100Mixed-positive evidence70% evidence 20.6/35 Income 24.5% · PAT 100% 71% evidence 11.7/25 ROA 1.2% · ROE 1.9% · GNPA — 68% evidence 5.5/20 P/BV 1.53× · P/BV÷ROE 0.81 70% evidence 13.2/20 RS sector 5.3% · RS bench 0.6% · 1Y 28.9%0 of 1 week ahead to 2026-07-02 70% evidence
Exact sum: 20.6 + 11.7 + 5.5 + 13.2 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14State Street CorporationSTT 49.7/100Mixed-negative evidence80% evidence LEADER 19.3/35 Income 12.3% · PAT 21.3% 81% evidence 8.9/25 ROA 0.3% · ROE 3.9% · GNPA — 68% evidence 6.9/20 P/BV 1.68× · P/BV÷ROE 0.43 70% evidence 14.6/20 RS sector 17.3% · RS bench 19% · 1Y 61.1%12 of 12 weeks ahead 100% evidence
Exact sum: 19.3 + 8.9 + 6.9 + 14.6 = 49.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Invesco Ltd.IVZ 48.9/100Mixed-negative evidence60% evidence BREAKING OUT 19.2/35 Income — · PAT — 26% evidence 10.8/25 ROA 1% · ROE 2.4% · GNPA — 68% evidence 7.4/20 P/BV 0.94× · P/BV÷ROE 0.39 70% evidence 11.5/20 RS sector 4.1% · RS bench 5.4% · 1Y 33.7%11 of 12 weeks ahead 100% evidence
Exact sum: 19.2 + 10.8 + 7.4 + 11.5 = 48.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Equitable Holdings, Inc.EQH 45.5/100Mixed-negative evidence76% evidence BREAKING OUT 11.8/35 Income -23.4% · PAT -126% 71% evidence 12.3/25 ROA 0.3% · ROE 24.1% · GNPA — 68% evidence 3.6/20 P/BV 38.27× · P/BV÷ROE 1.59 70% evidence 17.8/20 RS sector 9.3% · RS bench 10.6% · 1Y -0.6%12 of 12 weeks ahead 100% evidence
Exact sum: 11.8 + 12.3 + 3.6 + 17.8 = 45.5 · Decision use: Price leads the evidence: RS versus the benchmark is 10.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
17Franklin Resources, Inc.BEN 44.1/100Mixed-negative evidence60% evidence FADING 17.1/35 Income — · PAT — 26% evidence 8.6/25 ROA 0.4% · ROE 1.8% · GNPA — 68% evidence 5.7/20 P/BV 1.44× · P/BV÷ROE 0.8 70% evidence 12.7/20 RS sector 9.3% · RS bench 11% · 1Y 34%8 of 12 weeks ahead 100% evidence
Exact sum: 17.1 + 8.6 + 5.7 + 12.7 = 44.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Blue Owl Capital Inc.OWL 42.4/100Mixed-negative evidence60% evidence BREAKING OUT 19.5/35 Income — · PAT — 26% evidence 12.3/25 ROA 1.6% · ROE 1.9% · GNPA — 68% evidence 4.6/20 P/BV 2.94× · P/BV÷ROE 1.55 70% evidence 6.0/20 RS sector -22.9% · RS bench -22.3% · 1Y -46.5%7 of 12 weeks ahead 100% evidence
Exact sum: 19.5 + 12.3 + 4.6 + 6 = 42.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Raymond James Financial, Inc.this pageRJF 41.6/100Mixed-negative evidence80% evidence FADING 15.6/35 Income 10.5% · PAT 8.1% 81% evidence 10.9/25 ROA 0.7% · ROE 4.8% · GNPA — 68% evidence 6.7/20 P/BV 2.3× · P/BV÷ROE 0.48 70% evidence 8.4/20 RS sector -5.5% · RS bench -4.3% · 1Y -5.5%9 of 12 weeks ahead 100% evidence
Exact sum: 15.6 + 10.9 + 6.7 + 8.4 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Ares Management CorporationARES 40.7/100Mixed-negative evidence80% evidence ASLEEP 21.7/35 Income 24% · PAT 32.9% 81% evidence 10.2/25 ROA 0.7% · ROE 3.6% · GNPA — 68% evidence 3.4/20 P/BV 6.38× · P/BV÷ROE 1.77 70% evidence 5.4/20 RS sector -15.3% · RS bench -14.5% · 1Y -32.1%6 of 12 weeks ahead 100% evidence
Exact sum: 21.7 + 10.2 + 3.4 + 5.4 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21Blackstone Secured Lending FundBXSL 39.3/100Mixed-negative evidence62% evidence TURNING 9.5/35 Income -22.6% · PAT -19.1% 55% evidence 11.9/25 ROA — · ROE 3.4% · GNPA — 34% evidence 8.6/20 P/BV 0.9× · P/BV÷ROE 0.27 70% evidence 9.3/20 RS sector -8.3% · RS bench -7% · 1Y -10.2%0 of 12 weeks ahead 100% evidence
Exact sum: 9.5 + 11.9 + 8.6 + 9.3 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22TPG Inc.TPG 38.8/100Mixed-negative evidence64% evidence BREAKING OUT 17.1/35 Income 11.5% · PAT 100% 71% evidence 4.2/25 ROA -0.8% · ROE -3.4% · GNPA — 68% evidence 9.4/20 P/BV 5.73× · P/BV÷ROE — 10% evidence 8.1/20 RS sector -14.5% · RS bench -13.8% · 1Y -27.2%6 of 12 weeks ahead 100% evidence
Exact sum: 17.1 + 4.2 + 9.4 + 8.1 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23Apollo Global Management, Inc.APO 37.8/100Mixed-negative evidence80% evidence ASLEEP 18.3/35 Income 41.2% · PAT -17.5% 81% evidence 9.4/25 ROA 0.5% · ROE 5.5% · GNPA — 68% evidence 5.8/20 P/BV 3.24× · P/BV÷ROE 0.59 70% evidence 4.3/20 RS sector -9.9% · RS bench -8.8% · 1Y -14%0 of 12 weeks ahead 100% evidence
Exact sum: 18.3 + 9.4 + 5.8 + 4.3 = 37.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24KKR & Co. Inc.KKR 34.2/100Adverse evidence80% evidence ASLEEP 17.4/35 Income 31.1% · PAT 13.5% 81% evidence 6.9/25 ROA 0.1% · ROE 1.5% · GNPA — 68% evidence 4.2/20 P/BV 2.65× · P/BV÷ROE 1.77 70% evidence 5.7/20 RS sector -17.2% · RS bench -16.4% · 1Y -35%4 of 12 weeks ahead 100% evidence
Exact sum: 17.4 + 6.9 + 4.2 + 5.7 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25Blue Owl Capital CorporationOBDC 31.2/100Adverse evidence62% evidence TURNING 9.0/35 Income -11% · PAT -50.5% 55% evidence 9.9/25 ROA — · ROE 0.5% · GNPA — 34% evidence 4.8/20 P/BV 0.77× · P/BV÷ROE 1.53 70% evidence 7.5/20 RS sector -12.8% · RS bench -11.6% · 1Y -20.7%0 of 12 weeks ahead 100% evidence
Exact sum: 9 + 9.9 + 4.8 + 7.5 = 31.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26Brookfield CorporationBN 26.2/100Adverse evidence80% evidence ASLEEP 12.9/35 Income 1.8% · PAT 21% 81% evidence 8.7/25 ROA 0.7% · ROE 0.4% · GNPA — 68% evidence 3.8/20 P/BV 2.24× · P/BV÷ROE 5.6 70% evidence 0.8/20 RS sector -22.7% · RS bench -21.6% · 1Y -22.6%0 of 12 weeks ahead 100% evidence
Exact sum: 12.9 + 8.7 + 3.8 + 0.8 = 26.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
27The Carlyle Group Inc.CG 22.8/100Adverse evidence64% evidence ASLEEP 5.9/35 Income -28.9% · PAT -44% 71% evidence 5.9/25 ROA 0.3% · ROE -2.1% · GNPA — 68% evidence 9.6/20 P/BV 3.22× · P/BV÷ROE — 10% evidence 1.4/20 RS sector -28.5% · RS bench -27.6% · 1Y -41.3%2 of 12 weeks ahead 100% evidence
Exact sum: 5.9 + 5.9 + 9.6 + 1.4 = 22.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28Pershing Square Inc.PS 57.5/100Thin evidence · provisional42% evidence BREAKING OUT 29.2/35 Income 68.8% · PAT 100% 71% evidence 8.3/25 ROA 1% · ROE -35.8% · GNPA — 68% evidence 10.0/20 P/BV — · P/BV÷ROE — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y —3 of 8 weeks ahead 0% evidence
Exact sum: 29.2 + 8.3 + 10 + 10 = 57.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Ares Capital CorporationARCC 42.3/100Thin evidence · provisional46% evidence TURNING 16.5/35 Income — · PAT — 10% evidence 10.4/25 ROA — · ROE 1.2% · GNPA — 34% evidence 5.9/20 P/BV 0.96× · P/BV÷ROE 0.8 70% evidence 9.5/20 RS sector -8% · RS bench -6.7% · 1Y -10.2%1 of 12 weeks ahead 100% evidence
Exact sum: 16.5 + 10.4 + 5.9 + 9.5 = 42.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Raymond James Financial, Inc.'s stock price today?

Raymond James Financial, Inc. trades at $165, −5.5% over the past year. The company is valued at $32.0 B. The stock sits at 59% of its 52-week range of $141–$181, +2.2% versus its 200-day average. On the tape, the price is topping out, 6 weeks in. — as of 17 September 2026.

What were Raymond James Financial, Inc.'s latest quarterly results?

Raymond James Financial, Inc. reported total income of $3.9 B and net profit of $0.6 B for the Jun 26 quarter. Income rose 15.6% and profit rose 34.1% year on year. Earnings per share were $3.01. The net margin was 15.0%, 2.1 pp higher than a year earlier. — as of 17 September 2026.

What is Raymond James Financial, Inc.'s revenue?

Raymond James Financial, Inc. reported revenue of $3.9 B in the Jun 26 quarter, +15.6% year on year. For the full FY25 fiscal year, revenue was $14.1 B (+9.7%). Over the last 4 years revenue compounded at 9.6% a year. — as of 17 September 2026.

What is Raymond James Financial, Inc.'s profit?

Raymond James Financial, Inc. earned $0.6 B of net profit in the Jun 26 quarter, +34.1% year on year — the 2nd straight quarter of growth. Full-year FY25 profit was $2.1 B. The net margin ran 15.0% in the latest quarter. — as of 17 September 2026.

What is Raymond James Financial, Inc.'s market cap?

Raymond James Financial, Inc.'s market capitalisation is $32.0 B at a stock price of $165. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.

What is Raymond James Financial, Inc.'s P/BV ratio?

Raymond James Financial, Inc. trades at a P/BV of 2.5×, at the 68th percentile of its own 5-year range, against a long-run median of 2.5×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.

Does Raymond James Financial, Inc. pay a dividend?

Yes — Raymond James Financial, Inc. declared $0.54 per share for Jun 26, and $2.12 per share across the last four reported quarters. — as of 17 September 2026.

What is Raymond James Financial, Inc.'s dividend per share?

Raymond James Financial, Inc.'s most recently declared dividend is $0.54 per share for Jun 26, giving $2.12 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.

What is Raymond James Financial, Inc.'s dividend yield?

Raymond James Financial, Inc.'s trailing dividend yield is 1.29%: $2.12 declared per share across the last four reported quarters, against a share price of $165. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.

Is Raymond James Financial, Inc. overvalued?

On its own history, Raymond James Financial, Inc. looks expensive: its P/BV of 2.5× sits at the 68th percentile of its 5-year range (long-run median 2.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.

Is Raymond James Financial, Inc. growing?

Yes — Raymond James Financial, Inc. is growing: latest-quarter revenue +15.6% year on year, profit +34.1%, and the net margin +2.1 pp at 15.0%. The 4-year compound rates are 9.6% (revenue) and 11.1% (profit). The earnings engine currently reads: improving — as of 17 September 2026.

How is Raymond James Financial, Inc. performing?

Raymond James Financial, Inc. is topping out, 6 weeks in. Its latest quarter's income rose 15.6% and profit rose 34.1% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 12 weeks. This describes what the data did, not a rating. — as of 17 September 2026.

What stage is Raymond James Financial, Inc. in?

Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROE at 17.9% and holding. The read comes from the last 12 quarters of growth (revenue growth +10.5% latest, profit growth +7.5% latest, eps growth +12.5% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.

Is Raymond James Financial, Inc. in an uptrend?

It is stalling — the price is topping out (week 6 of stage 3), trading +2.2% versus its 200-day average and at 59% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.

Is Raymond James Financial, Inc. beating the market?

On recent form, yes — Raymond James Financial, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 12 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +393% against the S&P 500's +255% — ahead of the index over the full window. — as of 17 September 2026.

Will Raymond James Financial, Inc.'s stock price go up?

This page publishes no price forecast for Raymond James Financial, Inc. What it measures instead: the stock price is $165, the price is topping out 6 weeks in. Its P/BV of 2.5× sits at the 68th percentile of its own 5-year range. — as of 17 September 2026.

Is the market betting against Raymond James Financial, Inc.?

Somewhat — short interest is 4.6% of Raymond James Financial, Inc.'s tradable float, about 7.8 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.

Where is Raymond James Financial, Inc. in its business cycle?

Raymond James Financial, Inc.'s FY25 net margin was 15.1%, against a 5-year band of 13.7%–16.1%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 15.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.

What could break the Raymond James Financial, Inc. story?

Biggest watch item: the P/BV sits at the 68th percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.

Is Raymond James Financial, Inc. a stock worth studying right now?

This is not investment advice. The machine read: Raymond James Financial, Inc.'s earnings have outrun its stock. EPS grew +6.2% in a year against a −5.5% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-17. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI